Functional Characterization of Human CYP2C9 Allelic Variants in COS-7 Cells

被引:10
|
作者
Du, Huihui [1 ,2 ]
Wei, Zhiyun [1 ,2 ]
Yan, Yucai [1 ,2 ]
Xiong, Yuyu [1 ,2 ]
Zhang, Xiaoqing [3 ]
Shen, Lu [1 ,2 ]
Ruan, Yunfeng [1 ,2 ]
Wu, Xi [1 ,2 ]
Xu, Qingqing [1 ,2 ]
He, Lin [1 ,2 ,4 ]
Qin, Shengying [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, BioX Inst, Shanghai 200030, Peoples R China
[2] Shanghai Genome Pilot Inst Genom & Human Hlth, Shanghai, Peoples R China
[3] Shanghai Pulm Hosp, Dept Pharm, Shanghai, Peoples R China
[4] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China
来源
FRONTIERS IN PHARMACOLOGY | 2016年 / 7卷
关键词
cytochrome P450; genetic polymorphisms; pharmacokinetics; in vitro models; HPLC (high-performance/pressure liquid chromatography); S-warfarin; Chinese Han; HUMAN LIVER-MICROSOMES; IN-VITRO ASSESSMENT; AMINO-ACID; CYTOCHROME-P450; WARFARIN; POPULATION; METABOLISM; POLYMORPHISM; PHENYTOIN;
D O I
10.3389/fphar.2016.00098
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Variability in activity of CYP2C9, which is involved in the metabolism of approximately 15% of current therapeutic drugs, is an important contributor to interindividual differences in drug response. To evaluate the functional alternations of CYP2C9*2, CYP2C9*3, CYP2C9*8, CYP2C9*11 and CYP2C9*31, identified in our previous study in Chinese Han population, allelic variants as well as the wild-type CYP2C9 were transiently expressed in COS-7 cells. Kinetic parameters (Km. Vmax, and Clint) for S-warfarin 7-hydroxylation by these recombinant CYP2C9s were determined. Relative to CYP2C9.1, recombinant CYP2C9.3 and CYP2C9.11 exhibited significantly higher Km values, and all allelic variants showed significantly decreased Vmax and Clint values. Among all allelic variants, catalytic activity of CYP2C9.3 and CYP2C9.11 reduced the most (8.2% and 9.8% of Clint ratio, respectively; P < 0.001). These findings should be useful for predicting the phenotype profiles of CYP2C9 in Chinese Han population, comparing the functional results of these alleles accurately, and finally optimizing pharmacotherapy of drug treatment.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] The Role of Human CYP2C8 and CYP2C9 Variants in Pioglitazone Metabolism In Vitro
    Muschler, Eugen
    Lal, Jawahar
    Jetter, Alexander
    Rattay, Anke
    Zanger, Ulrich
    Zadoyan, Gregor
    Fuhr, Uwe
    Kirchheiner, Julia
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 (06) : 374 - 379
  • [32] Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes
    Miners, JO
    Coulter, S
    Birkett, DJ
    Goldstein, JA
    PHARMACOGENETICS, 2000, 10 (03): : 267 - 270
  • [33] Functional characterization of 9 CYP2A13 allelic variants by assessment of nicotine C-oxidation and coumarin 7-hydroxylation
    Kumondai, Masaki
    Hosono, Hiroki
    Maekawa, Masamitsu
    Yamaguchi, Hiroaki
    Mano, Nariyasu
    Oda, Akifumi
    Hirasawa, Noriyasu
    Hiratsuka, Masahiro
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : 82 - 89
  • [34] Prevalence of CYP2C9 variants in the Mexican population
    Aguilar, Bernardo
    Rojas, Julio C.
    Collados, Maria T.
    ARCHIVES OF MEDICAL RESEARCH, 2008, 39 (04) : 463 - 463
  • [35] Association of CYP2C9 Genetic Variants with Vitiligo
    Alzolibani, Abdullateef A.
    Al Robaee, Ahmad
    Al-Shobaili, Hani
    Al-Saif, Fahad
    Al-Mekhadab, Eman
    Settin, Ahmed A.
    ANNALS OF DERMATOLOGY, 2014, 26 (03) : 343 - 348
  • [36] Differential activation of CYP2C9 variants by dapsone
    Hummel, MA
    Dickmann, LJ
    Rettie, AE
    Haining, RL
    Tracy, TS
    BIOCHEMICAL PHARMACOLOGY, 2004, 67 (10) : 1831 - 1841
  • [37] Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone
    Hummel, Matthew A.
    Gannett, Peter M.
    Aguilar, Jarrett
    Tracy, Timothy S.
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2008, 475 (02) : 175 - 183
  • [38] Identification and drug metabolic characterization of four new CYP2C9 variants CYP2C9*72-*75 in the Chinese Han population
    Zhao, Fang-Ling
    Zhang, Qing
    Wang, Shuang-Hu
    Hong, Yun
    Zhou, Shan
    Zhou, Quan
    Geng, Pei-Wu
    Luo, Qing-Feng
    Yang, Jie-Fu
    Chen, Hao
    Cai, Jian-Ping
    Dai, Da-Peng
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [39] Dapsone activation of flurbiprofen and naproxen metabolism in CYP2C9*1 and CYP2C9*5 variants.
    Hummel, MA
    Rettie, AE
    Dickmann, LJ
    Tracy, TS
    FASEB JOURNAL, 2002, 16 (04): : A563 - A563
  • [40] CYP2C9 polymorphisms and CYP2C9*2 genotyping primers
    Goldstein, JA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 409 - 410